The Neurosurgery Signal — Signal, Not Noise

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1056/NEJMoa0808710

PMID

19228619

PICO

Population

Patients with CNS tumors, including WHO grade II-IV gliomas

Intervention

Detection of IDH1 or IDH2 mutations

Comparator

Wild-type IDH genes

Outcomes

Mutation frequency, genetic/clinical characteristics, overall survival

Design

Type

Observational cohort study

Randomized

Multicenter

Yes

Blinded

Not applicable: molecular analysis

Follow-up

Not specified in excerpt

Primary endpoint

Frequency of IDH1/IDH2 mutations in glioma subtypes

Secondary endpoints

Association with clinical characteristics
Overall survival difference

Practice impact

What this means

This landmark study identified IDH1/IDH2 mutations in >70% of grade II-III gliomas and secondary glioblastomas. Mutations define a distinct molecular subgroup with better survival, establishing IDH status as a key prognostic biomarker. While practice-changing for classification, therapeutic implications required subsequent trials.

Bottom line

IDH1/IDH2 mutations are common in adult gliomas and define a molecular subgroup with better prognosis

Strength of evidence

moderate

Recommendation

consider change

Why it matters

Establishes foundational biomarker for glioma classification
Changes prognostic stratification but not immediate treatment decisions

What would change my mind

Prospective validation in treatment-naïve cohorts
Randomized trials targeting IDH-mutant gliomas
Multivariate analysis controlling for age/grade/treatment

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Moderate: retrospective design with potential selection bias in tumor sampling

Confounding

Age and tumor grade likely confound survival analyses

Missing data

Not addressed in excerpt

Multiplicity

Multiple comparisons across tumor types without adjustment

Notes

Comprehensive molecular analysis across institutions
Functional validation of mutations

Stats check

NNT

N/A

Effect sizes

IDH1 mutations in >70% of WHO grade II-III astrocytomas/oligodendrogliomas
Better outcome with mutations (no specific HR provided)

Absolute effects

445 CNS tumors analyzed
494 non-CNS tumors analyzed

Concerns

Survival analysis descriptive without multivariate adjustment
No confidence intervals reported for mutation frequencies

External validity

Who it applies to

Patients with WHO grade II-IV gliomas, particularly younger patients with lower-grade tumors

Who it does not

Pediatric gliomas, non-glial CNS tumors

Generalizability notes

Multi-institutional cohort enhances generalizability
Retrospective nature limits causal inference

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 1 Methods

quote

We determined the sequence of the IDH1 gene and the related IDH2 gene in 445 central nervous system (CNS) tumors and 494 non-CNS tumors.

claim_id

stats_check.effect_sizes

locator

p. 2 Results

quote

We identified mutations that affected amino acid 132 of IDH1 in more than 70% of WHO grade II and III astrocytomas and oligodendrogliomas

claim_id

practice_impact.bottom_line

locator

p. 3 Results

quote

Tumors with IDH1 or IDH2 mutations had distinctive genetic and clinical characteristics, and patients with such tumors had a better outcome than those with wild-type IDH genes.

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years